These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2492446)

  • 41. Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs).
    Mehrez A; Gafni A
    Pharmacoeconomics; 1992 May; 1(5):338-45. PubMed ID: 10146998
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and economic factors in the selection of low-osmolality contrast media.
    Matthai WH
    Pharmacoeconomics; 1994 Mar; 5(3):188-97. PubMed ID: 10146894
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel monoclonal antiendotoxin antibody therapy: efficacy at any price?
    Fant WK
    Pharmacoeconomics; 1993 Jun; 3(6):437-45. PubMed ID: 10146878
    [No Abstract]   [Full Text] [Related]  

  • 44. Outcomes research and cost-effectiveness analysis in radiology.
    Hunink MG
    Eur Radiol; 1996; 6(5):615-20. PubMed ID: 8934123
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The standard gamble method: what is being measured and how it is interpreted.
    Gafni A
    Health Serv Res; 1994 Jun; 29(2):207-24. PubMed ID: 8005790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A methodology for the economic assessment of picture archiving and communication systems.
    Langlotz CP; Even-Shoshan O; Seshadri SS; Brikman I; Kishore S; Kundel HL; Schwartz JS
    J Digit Imaging; 1995 May; 8(2):95-102. PubMed ID: 7612707
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonionic contrast media: a bargain for some, a burden for many.
    Goel V; Deber RB; Detsky AS
    CMAJ; 1990 Sep; 143(6):480-1. PubMed ID: 2119872
    [No Abstract]   [Full Text] [Related]  

  • 48. Ionic versus nonionic contrast media: a burden or a bargain?
    Gafni A; Zylak CJ
    CMAJ; 1990 Sep; 143(6):475-8. PubMed ID: 2119871
    [No Abstract]   [Full Text] [Related]  

  • 49. Containing Ontario's hospital costs under universal insurance in the 1980s: what was the record?
    Detsky AS; O'Rourke K; Naylor CD; Stacey SR; Kitchens JM
    CMAJ; 1990 Mar; 142(6):565-72. PubMed ID: 2107020
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Down the Oregon trail--the way for Canada?
    Emson HE
    CMAJ; 1991 Dec; 145(11):1441-3. PubMed ID: 1822103
    [No Abstract]   [Full Text] [Related]  

  • 51. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.
    Laupacis A; Feeny D; Detsky AS; Tugwell PX
    CMAJ; 1992 Feb; 146(4):473-81. PubMed ID: 1306034
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonionic contrast media: economic analysis and health policy development.
    Goel V; Deber RB; Detsky AS
    CMAJ; 1989 Feb; 140(4):389-95. PubMed ID: 2492446
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Indications for the use of low-osmolar contrast agents.
    Bloom DM
    Physician Exec; 1989; 15(4):24-5. PubMed ID: 10313370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.